ULURU
Addison
About ULURU
ULURU is a specialty pharmaceutical company, engages in the research, development, and commercialization of wound care and mucoadhesive film products in the United States and internationally. The company’s products are based on patented Nanoflex and OraDisc drug delivery technologies. Its products include Altrazeal, a transforming powder dressing for the treatment of various wounds, such as partial-thickness burns, donor sites, and abrasions, as well as surgical, acute, and chronic wounds; Aphthasol and Aptheal for the treatment of canker sores; OraDisc A for the treatment of oral conditions, which rely upon the use of medications formulated as gels and pastes that are applied to lesions in the mouth; and OraDisc B, a mucoadhesive disc product for the treatment and management of oral pain. The company was founded in 1987 and is based in Addison, Texas.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Public
- Employees: 11 – 50
- Estimated revenue: $1K – $10K
- Total funding: $7.8M
- Funding stage: IPO
- Last round: Post-IPO Equity (Sep 2023)
- Ticker: otcqb:ULUR
- Website: uluruinc.com
- Phone: 2149055130
Industries & Categories
Biopharma, Biotechnology, Pharmaceutical
Social Profiles
Canonical: https://fsome.com/organization/uluru-175786 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.